BRAF and MEK Inhibitor-induced Acute Necrotizing Pancreatitis: A Case Report and Literature Review
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Abstract Colorectal cancer (CRC) with the BRAF V600E mutation is an aggressive subtype often resistant to conventional chemotherapy. While B-Raf proto-oncogene (BRAF) / Epidermal growth factor receptor (EGFR) inhibitor combinations are now standard for metastatic BRAF V600E CRC, these BRAF inhibitors can cause various adverse effects. Among these adverse effects, pancreatitis is a rare but serious complication that is often under-recognized due to current trials having limited durations and populations. We report the case of a 50-year-old female with metastatic BRAF V600E-mutant colon cancer who achieved an exceptional and durable complete response over 3 years with off-label dabrafenib and trametinib plus cetuximab. Notably, she developed acute necrotizing pancreatitis after more than 3 years of treatment, a significantly longer latency than previously reported, and experienced recurrence upon rechallenge. A literature review confirmed that pancreatitis is a rare complication across all Food and Drug Administration-approved BRAF inhibitors, with varying onset times. This case highlights the potential for late-onset, severe pancreatitis with prolonged BRAF inhibitor use. Given the increasing use of BRAF inhibitors, particularly in CRC, routine monitoring and further mechanistic research are required.
Fields of Study & Subjects
Colorectal Cancer Treatments and Studies
Pancreatic and Hepatic Oncology Research
Pancreatitis Pathology and Treatment
Publication details
- Journal / source
- Journal of Cancer Research and Practice
- Volume
- 13
- Issue
- 3
- Pages
- 113–117
- Publication date
- 26 March 2026
- Language
- EN